Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Clinical trial NCT06876142 · SUSPENDED

Trial details

NCT number: NCT06876142
Sponsor: National Cancer Institute (NCI)
Status: SUSPENDED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Relapsed and/or Refractory Multiple Myeloma (RRMM)

Start date: 2026-08-23
Primary completion: 2033-01-01
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.